logo
  

Biohaven Prices Offering Of $230 Mln Of Shares At $41/share; Stock Down In Pre-Market

Biohaven Ltd. (BHVN) on Thursday announced the pricing of its underwritten public offering of 5,609,757 shares at $41 per share for gross proceeds of around $230 million.

In addition, Biohaven has granted the underwriters a 30-day option to purchase up to 841,463 shares at the public offering price.

Biohaven intends to use the net proceeds for general corporate purposes.

The offering is expected to be closed on April 22.

J.P. Morgan, Morgan Stanley, TD Cowen, and Piper Sandler & Co. are acting as the joint lead book-running managers of the offering.

BHVN was trading down by 4.43 percent at $42.08 in the pre-market trade on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
Specialty medical devices provider Teleflex Inc. (TFX) reported Thursday that net income for the first quarter plunged to $15.29 million or $0.32 per share from $76.75 million or $1.62 per share in the prior-year quarter. Income from continuing operations was $0.33 percent, sharply lower than $1.63... Shares of Standard Chartered Plc were gaining more than 5 percent on the London Stock Exchange after the lending major reported Thursday higher profit in its first quarter, despite weak net interest income. The company further maintained its fiscal 2024 guidance. While reporting financial results for the first quarter on Wednesday, Kraft Heinz Co. (KHC) reaffirmed its adjusted earnings and organic net sales growth guidance for the full-year 2024. For fiscal 2024, the company still projects adjusted earnings in a range of $3.01 to $3.07 per share on organic...

This week, we feature OJEMDA’s FDA approval, Bristol Myer’s Job cuts, Novo Nordisk’s increased pricing of drugs in US, Incyte’s strategic acquisition, and Ireland’s Alcohol labels.

View More Videos
RELATED NEWS
Follow RTT